A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.

Affiliation

Carolina Urologic Research Center, Myrtle Beach, South Carolina, Spain. Electronic address: [Email]

Abstract

This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer.

Keywords

Androgen deprivation therapy,Efficacy,Leuprolide depot,Prostate cancer,Testosterone,

OUR Recent Articles